Omnicell, Inc. logo

Omnicell, Inc.

OMCL

NASDAQHealthcareMedical - Healthcare Information Services

Latest quote

$35.22

−$0.345 · -0.97%

Aug 24, 12:07 PM ET

OMCL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

51

Fair Value

Momentum

57

Neutral

Sentiment

73

Bullish

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Randall A. Lipps
Listed since
Aug 7, 2001
Employees
3,485

Market position

Volume
142.21K
0.2× average
Average volume
705.55K
Average daily volume
Market cap
1.6B USD
Beta
0.97
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.09B USD
EV / EBITDA
20.52×
Earnings yield
0.10%
Free cash flow yield
4.17%

Profitability & efficiency

Return on equity
0.17%
Return on assets
0.10%
Return on invested capital
0.14%

Financial health

Current ratio
1.43×
Altman Z-score
2.57
Piotroski F-score
8 of 9

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+72.22%
11 comparable reports
Latest EPS result
0.94
Estimate 0.47 · Beat by 101.07%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates10.710.420.14Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 0.6, estimate 0.57, surprise +5.26%, Beat. Q2 2025, reported May 6, 2025: actual 0.26, estimate 0.16, surprise +62.50%, Beat. Q3 2025, reported Jul 31, 2025: actual 0.45, estimate 0.31, surprise +45.16%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.51, estimate 0.36, surprise +41.67%, Beat. Q1 2026, reported Feb 5, 2026: actual 0.4, estimate 0.47, surprise -14.89%, Miss. Q2 2026, reported Apr 28, 2026: actual 0.55, estimate 0.33, surprise +66.67%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.94, estimate 0.468, surprise +101.07%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.42, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates326.54M300.16M273.77M247.38MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 306.88M USD, estimate 297.88M USD, surprise +3.02%, Beat. Q2 2025, reported May 6, 2025: actual 269.67M USD, estimate 259.94M USD, surprise +3.74%, Beat. Q3 2025, reported Jul 31, 2025: actual 290.56M USD, estimate 275.26M USD, surprise +5.56%, Beat. Q4 2025, reported Oct 30, 2025: actual 310.63M USD, estimate 295.6M USD, surprise +5.09%, Beat. Q1 2026, reported Feb 5, 2026: actual 313.98M USD, estimate 313.35M USD, surprise +0.20%, Beat. Q2 2026, reported Apr 28, 2026: actual 309.88M USD, estimate 304.02M USD, surprise +1.93%, Beat. Q3 2026, reported Jul 30, 2026: actual 312.21M USD, estimate 310.21M USD, surprise +0.64%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 304.43M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

9 institutions
Craig-HallummaintainBuy

OMCL news

OMCL peers

ETFs holding OMCL

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research OMCL

research.disclaimer